<DOC>
	<DOCNO>NCT01815450</DOCNO>
	<brief_summary>The purpose study compare safety efficacy BLI1100 formulation placebo treatment moderate severe acne vulgaris .</brief_summary>
	<brief_title>BLI1100-202 : BLI1100 Treatment Moderate Severe Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Males females 12 45 year age facial acne vulgaris Qualifying Investigator 's Global Assessment severity score Qualifying number noninflammatory lesion Qualifying number inflammatory lesion Facial hair ( beard ) , excessive scarring , sunburn disfigurement may obscure accurate assessment acne grade Using medication report exacerbate acne Any clinically relevant find baseline physical examination dermatological medical history severe systemic disease diseases facial skin Have know hypersensitivity previous allergic reaction component Patients participate investigational clinical , surgical , drug , device study within past 30 day Patients , opinion investigator , include study reason , include inability follow study procedure</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>